23 December 2021
Aiosyn, a company that develops AI-powered pathology algorithms for clinical diagnostics and life sciences, was awarded early-phase funding of Eur 250.000 by NWO (Dutch Research Council). This additional funding allows Aiosyn to accelerate its mission: increasing the adoption of artificial intelligence in pathology diagnostics and improving the chances of cancer patients worldwide.
Source: https://www.aiosyn.com/news/take-off-2-early-phase-funding/
Related news items
Investment in ARNE helps neonatologists make better decisions when treating newborn babies
28 April 2022 ARNE B.V. has raised financing from Oost NL and venture builder NLC. ARNE supplies smart software with which neonatologists can make decisions based on data after the birth of a child. read more.aspx?width=800&height=534&ext=.jpg&type=BlockColumn1Zoom1)
Aiosyn and Radboudumc are the first in the Netherlands to implement AI in the clinical pathology workflow Digital pathology slides will be screened with a quality control algorithm
4 April 2022 Aiosyn, a company that develops AI-powered computational pathology analysis for clinical diagnostics, and the department of pathology of Radboudumc, will collaborate to implement an algorithm for quality control of digitized histopathology tissue slides. read more
LUMO Labs and Oost NL invest in Aiosyn Investment accelerates development of artificial intelligence platform to improve diagnostics
7 February 2022 Aiosyn, a spin-off from Radboudumc, has received an investment from LUMO Labs. Oost NL is a co-investor. read moreDigital Health partners around Nijmegen join forces
26 January 2022 Health Valley has published a Digital Health Guide to connect Digital Health parties around Nijmegen and beyond. read more
Aiosyn has been selected for Techleap's Pole Position Program
28 October 2021 This program focuses on helping 10 ambitious companies within the medical field to reach the scaleup growth phase. read more